Ansuvimab |
Catalog No.GC72368 |
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2375952-29-5
Sample solution is provided at 25 µL, 10mM.
Ansuvimab blocks binding between the Ebola virus glycoprotein (GP) and the Niemann-Pick C1 receptor by binding to the LEIKKPDGS epitope located in the receptor binding site of the GP1 subunit of GP[1].
Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) against GP-transfected target cells, with maximal activity at the concentration of 0.03 μg/mL[2].
Ansuvimab results in all macaques surviving after exposure to a lethal dose of Ebola virus in on day 0[1].
References:
[1]. Lee A, et, al. Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598.
[2]. Corti D, et, al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science. 2016 Mar 18;351(6279):1339-42.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *